Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
Status:
Completed
Trial end date:
2019-11-25
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of
LIQ861, a dry powder formulation of treprostinil, in patients with Pulmonary Arterial
Hypertension (PAH). A secondary objective of this study is to evaluate the comparative
bioavailability of treprostinil between two formulations of inhaled therapy.